“… - gene replacement therapies, with either transplantation of sheets or topical application of emulgated/dispersed molecularly corrected cells/tissue (or corrective agents) onto sites of chronic wounding;
- topical applications, which offer vulnerable EB cohorts increased tolerability and feasibility and are of particular value for treating mucosal lesions and poorly accessible skin areas that are infeasible or challenging for skin grafting, like interdigital/intertriginous areas and face;
- skin grafting that is mainly restricted to sites of chronic and/or large blistering erosions to improve quality of life by reduction of itch, pain, inflammation, body fluid and protein loss while strengthening microbial defense and preventing cancer development in high‐risk long‐standing wounds;
- systemic and local immune modulation, for example iv stem cell infusions or ideally oral or liquid maintenance (immunomodulatory) therapies as booster, and topical agents like diacerein, calcipotriol;
- symptom‐relieving therapies, targeting distinct symptoms such as scarring (TGF‐β, TSP1 [ 104 ] and losartan [ 31,105 ), itch (dupilumab [ 31 ] ) and skin cancer (rigosertib, [ 7 ] pembrolizumab [ 72 ] and nivolumab (EudraCT 2016‐002811‐16));
- strategies for microbial surveillance (eg glucose peroxidase‐lactoperoxidase gel; hydrofiber dressings; quorum sensing), [ 15 ] and
- last but not least, various combinations of these approaches, applied in a complementary or synergistic fashion.
…”